

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Investigation of hallmarks of carbonyl stress and formation of end products in feline chronic kidney disease as markers of uraemic toxins

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1684922> since 2021-08-21T09:52:07Z

Published version:

DOI:10.1177/1098612X18783858

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Investigation of hallmarks of carbonyl stress and formation of end-products in feline Chronic Kidney Disease as markers of uremic toxins

§authors contributed equally

⁴ *Veterinary Clinics Valsusa, Avigliana, Italy*

Diana Vergnano DVM, ECVCN resident, Department of Veterinary Science,
University of Turin, Largo Paolo Braccini 2, 10095, Grugliasco (TO), Italy
E-mail: diana.vergnano@unito.it

Abstract

Objectives

Cats are commonly affected by chronic kidney disease (CKD). Many of the reactive carbonyl intermediates and end-products originating from the oxidative stress pathways are recognized as uremic toxins and may play a role in the progression of chronic renal failure. The aim of the present study is to confirm whether carbonyl stress and end product formation are higher in cats affected by CKD than in healthy cats and to assess whether angiotensin-converting-enzyme (ACE) inhibitors might affect these hallmarks.

Methods

Twenty-two cats were matched according to age and body condition score (BSC) and divided into three groups: control group (CG; n = 6), cats with chronic kidney disease (CKD; n = 11) and cats with chronic kidney disease treated with angiotensin-converting-enzyme (ACE) inhibitors (ACE; n = 5). Serum analysis was carried out to measure the levels of Pentosidine, Carboxymethyllysine, Advanced Oxidation Protein Products, Malondialdehyde, Methylglyoxal and Hexanoyl-Lysine. In addition, blood urea, creatinine, triglycerides, potassium, phosphorous, total proteins, glucose, urine protein to creatinine ratio and arterial systemic pressure were also evaluated. After checking for normality, comparisons between groups were performed followed by multiple-comparison tests. P values ≤ 0.05 were considered significant. Correlations between plasma

concentrations of the considered biomarkers and of the other metabolic parameters were investigated using Spearman's correlation coefficient.

Results (P)

Advanced oxidation protein products, malondialdehyde and hexanoyl-lysine concentrations were significantly higher in CKD and ACE treated groups compared with the control group ($P < 0.05$). The ACE group showed an increase in the levels of carboxymethyllysine when compared with the control group, whereas intermediate values of these biomarkers were found in the CKD group ($P < 0.05$). The highest values of carboxymethyllysine, advanced oxidation protein products and hexanoyl-lysine were found in the ACE treated group. By contrast, the CKD group showed the highest concentration of malondialdehyde. No statistically significant difference was found in the levels of pentosidine or methylglyoxal. Carbonyl stress and end-product formation correlated with creatinine and urea and with each other. Neither pentosidine nor methylglyoxal showed any correlation with other uremic toxins.

Conclusions and relevance

Significantly high concentrations of both intermediates and "end products" of carbonyl/oxidative stress, which are also uremic toxins, were detected in CKD cats. To date, the present study is the first to have concurrently taken into account several uremic toxins and biochemical parameters in cats affected by chronic kidney disease.

Introduction

The term “chronic kidney disease” (CKD) indicates an irreversible decrease in renal function, due to structural or functional defects in one or both kidneys.^{1,2} Cats, especially in geriatric age, are commonly affected by CKD.^{3,4} In human medicine, it has been shown that oxidative stress (OS) is associated with uremia.⁵ It has been hypothesized that two main events occur in CKD: the facilitation of inflammation and oxidative stress⁶ by uremic toxins; and the impairment of antioxidant enzymes in uremia.^{7,8} To our knowledge, only four studies evaluated oxidative stress in cats diagnosed with CKD: Yu and Paetau-Robinson⁹ conducted research on oxidative stress and the effects of dietary antioxidant supplementation; Keegan and Webb¹⁰ correlated oxidative stress parameters with neutrophil function; Krofic Zel et al¹¹ evaluated the activity of antioxidant systems; and Whitehouse et al¹² investigated the increase in urinary F2-Isoprostanes in different International Renal Interest Society (IRIS) stages of CKD.

OS is a complex phenomenon, which includes many pathways. Although it can be measured in different ways, the assessment of the by-products of OS reactions by means of biomolecules, like proteins, lipids and sugars, is the most common procedure. When reactive species act on lipids many peroxidation products are created, such as hydroperoxides, conjugated dienes, isoprostanes and derived carbonyls, such as malondialdehyde (MDA) and hydroxynonenal

(HNE).¹³ It has recently been shown that hexanoyl-lysine (HEL), another marker of fatty acid oxidation, is formed at an earlier stage of the cascade. This compound is a specific marker of omega-6 oxidation and promotes the formation of adducts from linoleic acid or arachidonic acid.¹⁴ Proteins are other molecules sensitive to the action of reactive species. Amino acids (AA) are prone to many reactions, including hydroxylation, nitration, sulphoxidation, chlorination, cross-linking and conversion to carbonyl derivatives.¹³

Of all the by-products originating from proteins damaged by OS, carbonyls, advanced oxidation protein products (AOPP) and adducts formed between AA and free carbonyls or lipid oxidation/reducing sugar products are the most extensively studied.¹³ The latter group of reactions consists of the addition of compounds deriving from glycation and lipid peroxidation to proteins:¹⁵ these reactions are also known as carbonylation. This modification is sustained by a surplus of reactive carbonyl compounds; in this circumstance, a series of different complex reactions lead to the formation of more stable final products, called “advanced end-products”, such as pentosidine (Pent) and carboxymethyllysine (CML). While Pent is a marker of the glycoxidative cascade and can be classified as an advanced glycation end product (AGE), CML is not only formed along this pathway but also during the lipoxidation cascade; thus, CML can also be considered an advanced lipoxidation end product (ALE) compound.¹⁶ An increase in these reactions is referred to as carbonyl stress and is related to the pathogenesis of several diseases, including chronic renal failure.¹⁷

From this brief summary, it is clear that OS creates a series of reactions leading to measurable by- and end-products; what it is known in human medicine is that reactive oxygen species (ROS) increase carbonyl stress¹⁸ and facilitate the formation of end-products, which themselves act as inducers of ROS in a vicious cycle (Figure 1). This tight relationship is present in uremic human patients affected by CKD, who show an increase in both carbonyl and oxygen reactive species.^{5,7} These molecules are recognized as uremic toxins and may play a role in the progression of chronic renal failure.

Over recent years, research into uremic toxicity has highlighted dozens of retention solutes that interact negatively with physiological mechanisms.¹⁹ Looking at the uremic database,²⁰ the only uremic toxins studied in feline medicine are creatinine (used for IRIS staging[???]), urea and MDA.⁹ Understanding how these substances are formed in chronic diseases can lead to the development of new therapeutic strategies. Currently, in cats affected by CKD, the main therapeutic goal attempts to reduce the progression of the disease.²¹ To date, the available approaches are based on the administration of proper diets (with the essential nutritional characteristics established by the Commission Regulation (EU) No 1123/2014) consisting of high quality proteins in reduced quantity and restricted levels of phosphorous). Moreover, according to other sources, this dietary regime should be supplemented with n-3 PUFA and antioxidants, dehydration should be corrected and drugs (such as calcium channel blockers and inhibitors of the renin-angiotensin-aldosterone system, i.e. angiotensin converting enzyme inhibitors-ACE or angiotensin receptor blockers

ARB)²² introduced to improve renal function, reduce blood pressure, and lower systemic oxidative stress.²¹ With regard to this last clinical recommendation, we previously reported that oral antihypertensive therapy exerts antioxidant activity, which scavenges reactive oxygen species in humans.²³

The aim of the present study is to confirm whether in cats affected by CKD, carbonyl stress and end product formation are higher than in healthy cats and to assess whether ACE inhibitors may affect these hallmarks.

Materials and Methods

Selection of cases

The study was carried out between January 2013 and June 2014. Twenty-two adult cats (9 neutered males and 13 neutered females) aged 4 to 14 years were enrolled. For each cat, a complete anamnesis was obtained and a physical examination, complete blood count (CBC), serum biochemistry and urinalysis performed. Residual samples from routine visits not related to the study were employed. Cat owners gave their consent to the use of surplus samples after routine testing.

The cats were divided into three groups: controls: CKD: and ACE. Animals comprising the control group (CG, n = 6) were enrolled during annual check-up examinations; the inclusion criteria for control animals were based on their clinical history and the absence of any disease on the basis of their anamnesis, physical examination, blood and urine analyses and the absence of medications except for parasitic control. The CKD group consisted of cats with

chronic kidney disease (n = 11) that had not been treated with any drugs in accordance with the clinician's recommendations and had been kept on a renal diet formulated by a diplomat from the European College of Veterinary and Comparative Nutrition (ECVCN). The recruitment of these cats was based on the diagnosis performed by a clinician and on the guidelines for IRIS staging of chronic kidney disease.²² The third group (ACE, n = 5) included cats affected by CKD, which were being treated with the specific diet and the ACE inhibitor hydrochloride (dosage regime was adapted and based on the values commonly recommended in clinical animal practice), administered for at least 40 days prior to sample collection. The inclusion criteria for CKD cats were based on a stable CKD history (in at least two separate time points) entailing anamnesis, physical examination, measurements of blood creatinine and confirmation of low urine specific gravity (<1035).

The inclusion criteria for all three groups were age (adult, centred on the mean age of the CKD cats) and Body Condition Score (BCS, 9 point scale, according to the American Animal Hospital Association, centred on the mean value for the CKD cats).

The exclusion criteria were the following: pre-renal or post renal azotemia, acute renal injury, acute infections, feline lower urinary tract disease (FLUTD), systemic metabolic disease (e.g., hyperthyroidism), diabetes, heart failure and positivity for feline leukaemia virus (FeLV) or feline immunodeficiency virus (FIV).

Sampling

Serum was collected and stored for 30 minutes at room temperature. Subsequently, it was separated by centrifugation (2500 g for 8 minutes) and two aliquots were obtained: one for the analysis of the biochemical and metabolic parameters, mainly related to the renal function, and one for the assessment of the carbonyl stress biomarkers, which constituted the target of the present study. Samples were stored at -80°C and analysed according to the procedures described in the following paragraphs. Urine samples were collected by cystocentesis when required by the clinician or by a non-invasive method (using a urine collection kit) and analysed within one hour by an automated analyser to obtain the urine protein to creatinine (UP/UC) ratio. Blood urea, (UREA), triglycerides (TG), potassium (K), phosphorous (P), creatinine (CREA) and total proteins (TP) were evaluated by an automated analyser. Plasma glucose (Glu) was determined in blood heparinised samples centrifuged within 15 minutes after sample collection. Systemic arterial pressure (SAP) measurement was taken using an indirect Doppler method via the radial pulse with the cat sitting or in sternal recumbency. The recorded value is the mean of five measurements.

Advanced end-products

All samples were analysed in duplicate.

Pentosidine (PENT)

Detection of pentosidine (PENT) was performed using high performance liquid chromatography (HPLC), according to Valle et al,²⁴ using a Waters system (Waters S.P.A., Milan, Italy). Briefly, protein content, after delipidation with hexane and precipitation with trichloroacetic acid, was hydrolysed with 6 mol/L hydrochloric acid for 18 h at 110°C in borosilicate screw-capped tubes, dried in a Speed-Vac concentrator and then reconstituted in HPLC-grade water containing 0.01 mol/L heptafluorobutyric acid (HFBA). Subsequently, it was filtered through a 0.45-µm pore diameter Ultrafree MC (Millipore, Milan, Italy) and injected into a Xterra C18 MS column (250 × 4.6 mm; Waters S.P.A., Milan, Italy) with a curvilinear gradient program of 20% – 40% methanol from 0 to 30 min and containing water (MilliQ, Millipore, Milan, Italy); both water and methanol contained 0.01 mol/L HFBA as a counterion. The PENT peaks were monitored using a Waters 2475 fluorescent detector (excitation 335 nm and emission 385 nm). A PENT synthetic standard (prepared as described by Grandhee and Monnier²⁵) was injected at the start of each run to determine PENT concentration in the sample using peak area comparison. The amount of PENT was expressed as pmol per mg of plasma protein content.

Carboxymethyllysine (CML)

Serum Carboxymethyllysine (CML) was evaluated by ELISA (EIAab, Wuhan, China), according to the manufacturer's instructions as reported by Bruynsteen et al.²⁶ The detection range of the CML ELISA kit was 0.78-50 ng/ml, therefore the serum samples were diluted 1:10. Absorbance was read at 450 nm using a microplate reader. The observed results were expressed as ng/ml.

Advanced oxidation protein products (AOPP)

Determination of AOPP was based on spectrophotometric analysis according to Bruynsteen et al.²⁶ AOPP concentration was measured by spectrophotometry on a microplate reader at λ 340 nm and was calibrated with a chloramine-T (CT) solution in presence of potassium iodide; briefly, 200 μ l of serum (diluted 1:10 with PBS) were placed on a 96-well microtiter plate, and 20 μ l of acetic acid were added. In standard wells, 10 μ l of 1.16 mol/L potassium iodide were added to 200 μ l of CT solution (0–100 μ mol/L) followed by 20 μ l of acetic acid. The absorbance of the reaction mixture was immediately read at 340 nm against a blank containing 200 μ l of PBS, 10 μ l of potassium iodide, and 20 μ l of acetic acid. The AOPP concentrations were expressed as μ mol/L of CT equivalents.

Carbonyls from the peroxidation cascade

Malondialdehyde MDA

Serum malondialdehyde was measured by HPLC according to the method published by Nielsen et al,²⁷ with slight modifications. Briefly, aliquots of serum were mixed (volume/volume) with a 0.6% (w/v) aqueous solution of thiobarbituric acid (TBA). The mixture was acidified with 1/20 volume of 100% (w/v) trichloroacetic acid and heated at 100°C for 1 hour. The samples were then cooled in ice and centrifuged at 13.000 g for 5 minutes. Aliquots of 50 μ l of the supernatant were injected into the HPLC system equipped with a Novapak C18 4 μ m 3.9x150 mm column (Waters S.P.A, Milan, Italy). The elution was

isocratic. The mobile phase consisted of a mixture of a 10 mM potassium dihydrogen phosphate solution, adjusted to pH 6.8 with KOH 1M, and methanol in a ratio of 60/40. The flow rate was 1 ml/min. Detection was performed by a spectrofluorometry (Ex/Em = 532/553 nm). Under our conditions, the peak of the MDA-TBA adduct was well resolved at a retention time of 4.8 min.

MDA concentration (nmol/ml) was calculated in reference to a calibration curve of MDA sodium salt standard according to the methodology developed by Nair et al²⁸. Concentration was expressed in nmol/ml.

Hexanoyl-Lysine HEL

Hexanoyl-Lys (HEL) was evaluated by ELISA (JalCA., Shizuoka, Japan), according to the manufacturer's instructions. The detection range of the HEL ELISA kit was 2-700 nmol/L. After overnight incubation with alpha-chymotrypsin, serum samples were ultrafiltered (cut-off 10kDa) and diluted 1:2. Absorbance was read at 450 nm. Results were expressed as nmol/mg protein.

Carbonyl from the glycoxidation cascade

Methylglyoxal MGO

Methylglyoxal was evaluated according to the method proposed by Wild et al,²⁹ with slight modifications. The method is based on the reaction between N-acetyl-L-cysteine (Sigma Aldrich) and methylglyoxal at room temperature. The reaction was performed in 100 mM sodium dihydrogen phosphate buffer

(adjusted to pH 7.0 with NaOH 10 M) at 22 °C. As the standard curve for the reaction, different concentrations of MG [???] (0.5, 1, 2, and 5 mM) were used. MG solutions (Sigma Aldrich) equating to 0.5, 2 and 5 mM were added to a volume of 980 µL with sodium dihydrogen phosphate. The reaction was started by adding 20 µL of 500 mM N-acetyl-L-cysteine and the absorption was recorded after 7 minutes. The condensation product, N- α -acetyl-S-(1-hydroxy-2-oxo-prop-1-yl) cysteine was determined by recording the absorption at 288 nm (UVIKON 923, Bio-Tek Instrument). Results were expressed as µmol/ml.

Serum protein content determination

Serum protein content was determined using the BCA protein assay kit according to the manufacturer's instructions (Thermo Fisher Scientific., Rockford, IL, USA).

Statistical analysis

Data were analysed using GraphPad Prism for Mac ,version 7.00 (GraphPad Software, La Jolla California USA, www.graphpad.com). All measurements were performed in duplicate and data were expressed as medians and interquartile ranges. After checking for normality using the Kolmogorov-Smirnov test, comparisons between groups were performed using the Kruskal–Wallis test followed by Dunn's multiple-comparison tests. P values <0.05 were considered significant (a “tendency” was considered for P < 0.1).

Relationships between plasma concentrations of the considered biomarkers and the other metabolic parameters were investigated using the one-tailed Spearman's correlation coefficient (rS).

Results

Results are illustrated in Tables 1 and 2. Comparison of the groups showed a significant increase in Crea and Urea in CKD and ACE treated groups, compared with healthy (CG) cats (Table1). No statistically significant differences were found between groups for TP, GLU, TG and K. The highest concentration of P was found in the CKD group, whereas the ACE treated group showed intermediate values. In both CKD and ACE treated groups UP/UC was higher in comparison with the control group.

Table1. Summary of laboratory findings for selected clinical parameters in CG, CKD and ACE treated cats, respectively. Data are reported as medians plus interquartile range (25th and 75th percentiles). Letters identify differences between group comparisons (P < 0.05).

	CG	CKD	ACE
CREA	1.20 ^a (1.05;1.48)	3.70 ^b (1.89;6.0)	2.10 ^b (1.95;3.40)
UREA	42.0 ^a (34.5;54.0)	73.0 ^b (59.0;188.0)	125.0 ^b (91.0;166.5)
TP	6.20 (5.95;7.05)	6.30 (5.7;7.0)	6.80 (5.55;7.10)
GLU	101.0 (99.0;103.5)	96.0 (83;107.0)	90.0 (79.0;120.0)
TG	29.0 (23.0;49.0)	44.0 (37.0;45.0)	35.0 (28.0;48.50)
K	4.30 (3.55;4.55)	4.90 (3.80;5.55)	4.50 (4.30;6.35)
P	4.20 ^a (4.0;5.65)	7.3 ^b (5.15;8.0)	5.10 ^{ab} (5.0;5.50)
UP/UC	0.21 ^a (0.20;0.27)	0.70 ^b (0.40;0.74)	1.60 ^b (1.10;3.10)
SAP	145.0 (140.0;155.0)	150.0 (140.0;230.0)	155.0 (135.0;187.50)

CREA: creatinine (mg/dl); TP: total proteins (g/dl); GLU: glucose (mg/dl); TG: triglycerides (mg/dl); K: potassium (mEq/l); P: phosphorus (mEq/l); UP/UC: urine protein to creatinine ratio; SAP: systemic arterial pressure (mmHg).

AOPP, MDA and HEL concentrations were significantly higher in CKD and ACE treated groups in comparison with the control (CG) group. When compared with CG, CML was higher in ACE, whereas CKD showed intermediate values. ACE treated groups were characterized by the highest values of CML, AOPP and HEL; conversely, the CKD group showed the highest concentration of MDA. The levels of PENT and MGO showed no statistical differences between groups (Tab.2).

Table 2 Advanced glycated end-products and carbonyl compounds in CG, CKD and ACE cats. Data are reported as medians plus interquartile range (25th and 75th percentiles). Letters identify differences between group comparisons (P < 0.05)

	CG	CKD	ACE
CML	13.81 ^a (11.64;19.46)	25.34 ^c (21.89;43.08)	42.85 ^b (33.11;65.43)
AOPP	83.61 ^a (66.2;103.9)	189.3 ^b (120.2;288.6)	247.1 ^b (137.0;368.9)
PENT	2.23 (0.63;5.77)	1.47 (1.09;4.33)	1.47 (1.28;3.89)
MGO	360.90 (226.20;531.00)	283.40 (177.61;362.00)	261.00 (240.30; 370.70)
MDA	4.85 ^a (3.80;8.79)	27.02 ^b (17.74;48.85)	24.70 ^b (15.42;58.21)
HEL	0.26 ^a (0.16;0.35)	0.88 ^b (0.62;1.12)	1.26 ^b (0.43;2.31)

CML: carboxymethyllysine (ng/ml); AOPP: advanced oxidation protein products (μmol/L of CT equivalents/mg protein); PENT: pentosidine (pmol/mg protein); MGO: methylglyoxal (μmol/ml); MDA: malondialdehyde (nmol/ml); HEL: hexanoyl-lysine (nmol/mg protein).

Crea was positively correlated with CML (r_s 0.49, $P < 0.05$), AOPP (r_s 0.56, $P < 0.05$), MDA (r_s 0.47, $p < 0.05$), and HEL (r_s 0.50, $p < 0.05$). It was also correlated with laboratory findings for selected clinical parameters as Urea (r_s 0.79, $P < 0.0001$), P (r_s 0.57, $P < 0.05$) and UP/UC (r_s 0.64, $P < 0.01$). Urea was positively correlated to CML (r_s 0.46, $P < 0.05$), AOPP (r_s 0.62, $P < 0.01$), MDA (r_s 0.72, $P < 0.0001$), and HEL (r_s 0.56, $P < 0.05$), as well as to K (r_s 0.52, $P < 0.05$) and UP/UC (r_s 0.65, $P < 0.01$).

HEL was positively correlated with CML (r_s 0.48, $P < 0.05$), AOPP (r_s 0.76, $P < 0.0001$), MDA (r_s 0.90, $P < 0.0001$) and K (r_s 0.60, $P < 0.01$).

AOPP was positively correlated with CML (r_s 0.56, $P < 0.05$), MDA (r_s 0.75, $P < 0.0001$), P (r_s 0.48, $P < 0.05$) and UP/UC (r_s 0.54, $P < 0.05$).

MDA was positively correlated with K (r_s 0.65, $P < 0.01$) and UP/UC (r_s 0.54, $P < 0.01$) and to CML (r_s 0.36, $P = 0.05$). CML was negatively correlated with GLU (r_s -0.482, $P < 0.05$). MGO was negatively correlated with K (r_s -0.574, $P < 0.05$). PENT was only positively correlated with SAP (r_s 0.46, $P < 0.05$).

The correlation table is provided as supplementary data.

Discussion

The present study focuses on hallmarks of oxidative stress and carbonyl stress in feline CKD. Significantly higher concentrations of intermediates and "end products" of carbonyl/oxidative stress, which are also uremic toxins, were detected in nephropathic cats.

An increased concentration of creatinine and urea and an increase in the urine protein to creatinine ratio (UP/UC, indicating proteinuria associated with kidney disease, provided that pre-renal and post-renal causes are excluded) were observed in CKD and ACE treated cats. ACE inhibitors, like benazepril, have been shown to reduce proteinuria in cats³⁰; however, in the present study, UP/UC in the ACE treated group was even higher than in the other group. The late initiation of the therapy (introduced 40-60 days before sample collection) can probably explain such a difference.

Over 100 substances have been classified as uremic toxins by the European Uremic Toxin (EUTox) Work Group²⁰ and recent studies have thoroughly categorised these different molecules. Urea and creatinine are the most common uremic toxins that can increase in cats with CKD and, as expected, in our study both of them increased in the cats with CKD. These compounds are soluble in water, have low molecular weights, and are classified by EUTox as the most reliable biomarkers for the evaluation of renal failure.³¹ Not surprisingly, in our study, Urea and Crea showed a positive correlation with each other as well as with UP/UC. In fact, an increase in these parameters typically occurs in CKD cats, and it is used as a diagnostic tool according to the IRIS staging of CKD²².

However, several other metabolites, other than these compounds, contribute to the toxic environment caused by the disease.³¹ Their concentrations provide insight into the clinical severity of CKD and favour the maintenance of both oxidative and carbonyl stress in a vicious circle.

In addition, Crea and Urea positively correlated with CML, AOPP, MDA and HEL, confirming an association with two recognized markers of renal failure in feline medicine. In particular, a statistically significant increase of CML, AOPP, HEL and MDA was found in the cats affected by CKD. By contrast, they showed a negligible increase in PENT and MGO. These differences were also consistently observed in the ACE treated group.

AOPP are a cluster of oxidative products derived from proteins and are recognised as markers of protein oxidative damage and of inflammation severity. The injured proteins are generated through a mechanism involving free radical direct oxidation of amino acids (e.g., tyrosine (Tyr), lysine (Lys), proline (Pro), arginine (Arg), etc.) (Dean et al 1997 [This should be added to the References]), and as an indirect consequence of lipoperoxidation.

AOPP are also defined as "accumulated solutes, normally excreted by the kidneys, that interact negatively with biological functions".¹⁵

It has been reported that serum AOPP concentration (closely correlated with other markers) increases with the progression of chronic diseases.^{32,33}

Accumulation of plasma and renal AOPPs is a common pathologic finding in human patients with CKD.³⁴ Witko-Sarsat et al^{32,33} showed that *in vivo* levels of AOPP correlated well with creatinine clearance.

In human studies of uremic patients, the concentration of plasma AOPP is related to the oxidative activity of circulating neutrophils, suggesting that these leukocytes might be involved in plasma AOPP formation through the myeloperoxidase/H₂O₂ system. In agreement with this hypothesis, Keegan and

Webb¹⁰ reported that the neutrophil oxidative burst is higher in chronic renal failure. Moreover, recent studies showed alterations in neutrophil oxidative metabolism and oxidative stress in dogs with CKD.³⁵⁻³⁹

Neutrophils can, therefore, be a source of pro-oxidant molecules contributing to an abnormal production of ROS and participating to the formation of AOPPs. Neutrophil oxidative metabolism can, in turn, be activated by other uremic toxins.³⁹

In accordance with the above mentioned findings, our study demonstrates for the first time a significant increase in AOPP in cats. In fact, when compared with control animals, CKD and ACE treated cats showed a 77% and 132% increase, respectively, in this parameter. AOPP are good hallmarks of the progression of chronic renal failure and the severity of uremia;⁴⁰ accordingly, in our study their concentrations correlated well with those of creatinine and urea. As previously reported, they are also a good and accurate biomarker of oxidative stress,⁴¹ and in the present study significant correlations with other markers of lipoperoxidation were found (CML, MDA, HEL).

Serum MDA [??] is an organic and very simple compound and one of the highly reactive carbonyls originating from PUFA oxidation (in particular from peroxidation of arachidonic, eicosapentaenoic and docosahexaenoic acid).⁴² In humans, it is the most abundant product, since it comprises 70% of all the carbonyls obtained by lipid peroxidation.¹⁸

In this study, serum MDA consistently increased in CKD (284%) and in ACE treated (256%) cats. An increase in serum MDA was previously observed in CKD

426 cats by Yu and Paetau-Robinson⁹ and four weeks of antioxidant supplements did
427 not exert any effect on this parameter.

428 MDA correlates with AOPP, HEL and with other markers of CKD (creatinine,
429 urea, Potassium and PU/CU): the remarkably high correlation with HEL ($r =$
430 $+0.904$) is explained by their shared origin from lipid peroxidation.

431 Since potassium did not vary significantly between groups but it often varies in
432 CKD cats⁴³ according to diet intake, the positive correlation with MDA is
433 probably suggestive of an increased oxidative stress in cats with higher
434 potassium quartiles, although still in the normal range.

435 Hexanoyl-lysine (HEL) is a recently discovered lipid peroxidation biomarker
436 derived from the oxidation of omega-6 unsaturated fatty acids.¹⁴ HEL is formed
437 when a lipid hydroperoxide links to a lysine residue, forming a stable
438 compound.⁴⁴ Arachidonic acid is one of the PUFA that, after oxidation, gives rise
439 to MDA and HEL compounds;⁴² it is often added to cat food, especially during
440 growth, gestation and lactation, because these animals are unable to synthesize
441 it.⁴⁵

442 The actual estimated requirements, based on a low reported synthesis capacity,
443 is 8 mg/100 g dry matter [??] (DM), considering a metabolic energy requirement
444 (MER) of 75 kcal/kg^{0.67[??]} in adult animals and 20 mg/100 g DM during growth
445 and reproduction⁴⁶. Arachidonic acid is naturally present in animal tissues, so it
446 does not have to be added to food containing proteins of animal sources.⁴⁵

447 When compared with control cats, CKD and ACE treated cats showed highly
448 significant increases in serum HEL (three times higher than controls in the CKD

group and five times higher than controls in ACE cats). Therefore, it would be interesting to evaluate whether a high content of arachidonic acid in the diet of CKD cats might generate oxidants and promote oxidative stress, as observed in CKD disease; if that were the case, more attention should be paid to the total amount of this substance provided to cats, in particular to those affected by CKD. The diet should be balanced with an equivalent amount of antioxidants to avoid the increase of carbonyls, such as MDA and HEL, originating from the peroxidation cascade.

CML is formed during the Maillard reaction by a process of glycoxidation. It can derive from different compounds, such as aldoses, ketoses, ascorbate, PUFAs and other molecules, and it is classified as an advanced glycation-lipoxidation end-product (AGE). Another relevant source of CML is from food. It is found in dairy products, but also in meat, fish, cereal-derived products, and in a group of fruit and vegetables that have been cooked or treated in an industrial context.¹⁶

As previously shown⁴⁷, CML increases in uremic patients and such an increase is also generally paralleled by increased levels of PENT,⁴⁷ since they share the same molecular origin. In the present study, CML levels increased 3-fold in the ACE treated group and doubled in the CKD group, but, intriguingly, a correlation with PENT was not observed.

We might hypothesize that although CML mainly derives from the peroxidation cascade, diet may also play a noteworthy role. Hull et al⁴⁸ showed that the CML content of cat food can be high. High exposure to CML should be

taken into careful consideration because this compound could be hazardous for feline health. This is even more true in cats with CKD, since CML seems to be associated with degenerative disorders and chronic kidney diseases.⁴⁹

Interestingly, CML levels are positively correlated with markers of kidney function, such as Crea and Urea, and negatively correlated with serum glucose, indicating that, in cats, high glucose might not lead to the formation of AGEs through the Maillard reaction. Other significant correlations were found with HEL ($P < 0.05$) and AOPP ($P < 0.05$), which can therefore be included, as is the case for humans, in the array of toxins found in uremic cats.

Methylglyoxal is generated by a series of metabolic pathways, mostly belonging to the glycolytic process. It is an important precursor of advanced glycation end products, being a highly powerful glycating agent. It is also involved in diabetic microvascular complications.⁵⁰ Increases in MGO have been observed during hyperglycaemia as well as in the uremic state.

In our study, MGO was not significantly different between the three groups of cats. Therefore, we can hypothesize that, in contrast to what has been observed in humans [perhaps a reference should be added here], the glycation pathway does not play a role in the pathophysiology of uremia in cats.

Pentosidine is a well-known advanced glycation end product and a uremic toxin, that, surprisingly, the levels of which were not, surprisingly, significantly different in the three groups of our study. This finding differs from what has been reported in human patients affected by CKD. In these cases a marked increase of pentosidine was found and also associated with a low glomerular filtration rate,

495 oxidative stress and inflammation.⁵¹⁻⁵³ In our opinion, in feline CKD, lipids and
496 lipoperoxidation seem to play a more important role than glucose, glycation or
497 glycoxidation, which seem to be unrelated to this disease. In cats, a distinct
498 pathway for the formation and accumulation of uremic toxins should be
499 considered, along with different uremic oxidative stress compounds. In line with
500 this reasoning, PENT might turn out to be a minor end product in the bulk of
501 AGEs.

502 In addition, in our groups of cats, PENT does not correlate with other carbonyl
503 determinations and other clinical parameters, although it does with SAP. We can
504 hypothesize that, in cats, pentosidine accumulation is, as in humans: age related:
505 connected with the progression of renal failure: and occurring mainly in tissues
506 rather than in blood. Tissue accumulation of PENT is well described in humans
507 and in other animals such as rats with CKD (where it accumulates in the
508 tubules),⁵⁴ dogs, rabbits, monkeys, etc. Moreover, in cats with CKD, an interstitial
509 fibrosis has been observed.⁵⁵ Pentosidine accumulation may occur in the kidneys
510 or in the artery walls, contributing to an increase in blood pressure. It is
511 noteworthy that, in humans, serum pentosidine is positively associated with
512 arterial stiffness and thickness.⁵⁶ Further studies are needed to evaluate this
513 intriguing hypothesis.

514 According to our results, the use of ACE inhibitors exerted a negligible effect on
515 the carbonyl oxidative stress status. By contrast, Monacelli et al²³ reported, in
516 humans, that valsartan, an angiotensin II receptor antagonist, besides having
517 antihypertensive activity, is also effective in scavenging oxidative stress species.

However, some differences between the present study and that of Monacelli et al²³ should be considered. Our experimental animals only received the therapy for 40-60 days, while the trial reported by Monacelli et al²³ lasted 6 months. The difference in the duration of the treatment may explain the lack of efficacy reported in our study. Such a difference could also be due to the use of a different type of drug. In fact, in our experiment cats were treated with benazepril, an angiotensin-converting-enzyme inhibitor, whereas in the study carried out by Monacelli et al²³, human patients received valsartan, an AT1 antagonist. Although carefully designed, our study suffers from some limitations, mainly due to its small sample size. In particular, it would have been more appropriate to enrol a larger number of cats for each IRIS stage (from 1 to 4) in order to draw more valid conclusions. The progression of uremic toxin production and/or the existence of a CKD threshold for their formation is also a matter of debate and deserves further investigation. Even if we had just included cats fed a renal diet, we would still have had confounding effects. In fact, renal diets of different brands can also vary in terms of omega 3-6, protein, phosphorus and carbonyl content. Further studies focusing on the intake of single diet components are required.

Conclusions

To the best of our knowledge, this is the first study to take into account contemporaneously several uremic toxins - according to the EUTox database - and biochemical parameters in cats affected by CKD. Evidence of strong carbonyl

stress is confirmed in CKD cats, irrespective of the therapy with ACE inhibitors. These toxic molecules contribute to maintaining and promoting oxidative stress and facilitate the progression of systemic damage. However, two markers Pentosidine and Methylglyoxal remained unaffected. This phenomenon suggests some hypotheses that need to be verified and, at the same time, raises the possibility that the disease might be characterized by a new pattern of markers. The significant and striking increases in CML and HEL offer challenging possibilities in terms of specific diets aimed at the prevention of kidney disease. Currently, more studies are needed to clarify the disease mechanisms and their associations with clinical signs, cellular damages and kidney malfunction in affected cats.

The results of the present study broaden our understanding of this widespread problem afflicting feline health and help pave the way towards new research fields required to make substantial progress in clinical veterinary practice.

Acknowledgments

We thank Dr Bruno Tasso (DIFAR, University of Genova, Italy) for the synthesis of MDA sodium salt and Dr Marco Maimone Clinica Veterinaria Foce for his help in the recruitment of the animals.

Authors' note

Part of the data were presented at the 2015 ESVCN conference.

Conflict of interest

The authors declare no potential conflicts of interest with respect to the research, authorship and publication of this article.

Funding

This study was partially supported by Candioli SPA.

References

1. Piyarungsri K, Pusoonthornthum R. **Risk and protective factors for cats with naturally occurring chronic kidney disease.** *J Feline Med Surg* 2016; 19: 358–363.
2. Polzin DJ. **Chronic kidney disease in small animals.** *Vet Clin North Am Small Anim Pract* 2011; 41: 15–30.
3. Ferlizza E, Campos A, Neagu A, et al. **The effect of chronic kidney disease on the urine proteome in the domestic cat (*Felis catus*).** *Vet J* 2015; 204: 73–81.
4. Vergnano D, Valle E, Bruni N, et al. **Effectiveness of a Feed Supplement in Advanced Stages of Feline Chronic Kidney Disease.** *Acta Sci Vet* 2016; 44: 1–8.
5. Miyata T, Kurokawa K, van Ypersele de Strihou C. **Relevance of oxidative and carbonyl stress to long-term uremic complications.** *Kidney Int* 2000; 58: S120–S125.
6. Small DM, Coombes JS, Bennett N, et al. **Oxidative stress, anti-oxidant therapies and chronic kidney disease.** *Nephrology* 2012; 17: 311–321.

- 588 7. Sundaram MS, Nagarajan S, Jagdeeshwaran A, et al. **Chronic Kidney**
589 **Disease — Effect of Oxidative Stress.** *Chinese J Biol* 2014; 2014: 1–6.
- 590 8. Jaisson S, Gillery P. **Evaluation of nonenzymatic posttranslational**
591 **modification-derived products as biomarkers of molecular aging of**
592 **proteins.** *Clin Chem* 2010; 56: 1401–1412.
- 593 9. Yu S, Paetau-Robinson I. **Dietary supplements of vitamins E and C and**
594 **beta-carotene reduce oxidative stress in cats with renal insufficiency.**
595 *Vet Res Commun* 2006; 30: 403–413.
- 596 10. Keegan RF, Webb CB. **Oxidative Stress and Neutrophil Function in Cats**
597 **with Chronic Renal Failure.** 2010; 24: 514–519.
- 598 11. Krofič Žel M, Tozon N, Nemec Svete A. **Plasma and Erythrocyte**
599 **Glutathione Peroxidase Activity, Serum Selenium Concentration, and**
600 **Plasma Total Antioxidant Capacity in Cats with IRIS Stages I-IV**
601 **Chronic Kidney Disease.** *J Vet Intern Med* 2014; 28: 130–6.
- 602 12. Whitehouse W, Quimby J, Wan S, et al. **Urinary F 2 -Isoprostanes in Cats**
603 **with International Renal Interest Society Stage 1-4 Chronic Kidney**
604 **Disease.** *J Vet Intern Med* 2017; 31: 449–456.
- 605 13. Piroddi M, Stefanelli L, Buzzelli D, et al. **Oxidative Stress in Acute**
606 **Kidney Injury and Sepsis.** In: Ronco C, Bellomo R, Kellum J (eds) *Critical*
607 *Care Nephrology*. Philadelphia: Saunders Elsevier, 2009, pp. 192–196.
- 608 14. Fukuchi Y, Miura Y, Nabeno Y, et al. **Immunohistochemical detection of**
609 **oxidative stress biomarkers, dityrosine and N(epsilon)-**
610 **(hexanoyl)lysine, and C-reactive protein in rabbit atherosclerotic**

- 611 **lesions.** *J Atheroscler Thromb* 2008; 15: 185–92.
- 612 15. Florens N, Calzada C, Lyasko E, et al. **Modified lipids and lipoproteins**
613 **in chronic kidney disease: A new class of uremic toxins.** *Toxins (Basel)*
614 2016; 8: 1–27.
- 615 16. Delgado-Andrade C. **Carboxymethyl-lysine: thirty years of**
616 **investigation in the field of AGE formation.** *Food Funct* 2015; 7: 46–57.
- 617 17. Katsuta N, Ohnuma T, Maeshima H, et al. **Significance of measurements**
618 **of peripheral carbonyl stress markers in a cross-sectional and**
619 **longitudinal study in patients with acute-stage schizophrenia.** *Schizophr*
620 *Bull* 2014; 40: 1366–1373.
- 621 18. Semchyshyn H, Lushchak I. **Interplay Between Oxidative and Carbonyl**
622 **Stresses : Molecular Mechanisms , Biological Effects and Therapeutic**
623 **Strategies of Protection.** In: Lushchak V, Semchyshyn HM (eds) *Oxidative*
624 *Stress - Molecular Mechanisms and Biological Effects.* InTech, 2012, pp. 15–45.
- 625 19. Duranton F, Cohen G, De Smet R, et al. **Normal and Pathologic**
626 **Concentrations of Uremic Toxins.** *J Am Soc Nephrol* 2012; 23: 1258–1270.
- 627 20. (ESAO) European Work Group on Uremic toxins (EUTox) of the
628 European Society for Artificial Organs. **Uremic Toxin - Data**
629 **Base**<http://www.uremic-toxins.org/DataBase.html> (accessed 10 October
630 2017).
- 631 21. Brown SA. **Oxidative Stress and Chronic Kidney Disease.** *Vet Clin North*
632 *Am - Small Anim Pract* 2008; 38: 157–166.
- 633 22. IRIS International Renal Interest Society. **IRIS Treatment**

Recommendations for CKD<http://www.iris->

[kidney.com/guidelines/recommendations.html](http://www.iris-kidney.com/guidelines/recommendations.html) (accessed 11 October 2017).

23. Monacelli F, Poggi A, Storace D, et al. **Effects of valsartan therapy on protein glycoxidation.** *Metabolism* 2006; 55: 1619–1624.
24. Valle E, Storace D, Sanguineti R, et al. **Association of the glycoxidative stress marker pentosidine with equine laminitis.** *Vet J* 2013; 196: 445–450.
25. Grandhee SK, Monnier VM. **Mechanism of formation of the maillard protein cross-link pentosidine: Glucose, fructose, and ascorbate as pentosidine precursors.** *J Biol Chem* 1991; 266: 11649–11653.
26. Bruynsteen L, Janssens GPJ, Harris PA, et al. **Changes in oxidative stress in response to different levels of energy restriction in obese ponies.** *Br J Nutr* 2014; 112: 1402–1411.
27. Nielsen F, Mikkelsen BB, Nielsen JB, et al. **Plasma malondialdehyde as biomarker for oxidative stress: Reference interval and effects of life-style factors.** *Clin Chem* 1997; 43: 1209–1214.
28. Nair V, Vietti DE, Cooper CS. **Degenerative Chemistry of Malondialdehyde. Structure, Stereochemistry, and Kinetics of Formation of Enaminals from Reaction with Amino Acids.** *J Am Chem Soc* 1981; 103: 3030–3036.
29. Wild R, Ooi L, Srikanth V, et al. **A quick, convenient and economical method for the reliable determination of methylglyoxal in millimolar**

- 657 **concentrations: The N-acetyl-L-cysteine assay.** *Anal Bioanal Chem* 2012;
658 403: 2577–2581.
- 659 30. King JN, Gunn-Moore D a, Tasker S, et al. **Tolerability and efficacy of**
660 **benazepril in cats with chronic kidney disease.** *J Vet Intern Med* 2006; 20:
661 1054–1064.
- 662 31. Lisowska-Myjak B. **Uremic toxins and their effects on multiple organ**
663 **systems.** *Nephron - Clin Pract* 2014; 128: 303–311.
- 664 32. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. **Advanced**
665 **oxidation protein products as a novel marker of oxidative stress in**
666 **uremia.** *Kidney Int* 1996; 49: 1304–1313.
- 667 33. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. **Advanced**
668 **oxidation protein products as novel mediators of inflammation and**
669 **monocyte activation in chronic renal failure.** *J Immunol* 1998; 161: 2524–
670 32.
- 671 34. Cao W, Hou FF, Nie J. **AOPPs and the progression of kidney disease.**
672 *Kidney Int Suppl* 2014; 4: 102–106.
- 673 35. Almeida BFM, Narciso LG, Melo LM, et al. **Leishmaniasis causes**
674 **oxidative stress and alteration of oxidative metabolism and viability of**
675 **neutrophils in dogs.** *Vet J* 2013; 198: 599–605.
- 676 36. Almeida BFM, Narciso LG, Bosco AM, et al. **Neutrophil dysfunction**
677 **varies with the stage of canine visceral leishmaniosis.** *Vet Parasitol* 2013;
678 196: 6–12.
- 679 37. Bosco AM, Pereira PP, Almeida BFM, et al. **Free p-Cresol Alters**

- 680 **Neutrophil Function in Dogs.** *Artif Organs* 2016; 40: 480–488.
- 681 38. Silva ACRA, de Almeida BFM, Soeiro CS, et al. **Oxidative stress,**
682 **superoxide production, and apoptosis of neutrophils in dogs with**
683 **chronic kidney disease.** *Can J Vet Res* 2013; 77: 136–141.
- 684 39. Bosco AM, Almeida BFM, Pereira PP, et al. **The uremic toxin**
685 **methylguanidine increases the oxidative metabolism and accelerates**
686 **the apoptosis of canine neutrophils.** *Vet Immunol Immunopathol* 2017; 185:
687 14–19.
- 688 40. Kimoto Y, Sugiyama A, Nishinohara M, et al. **Expressions of protein**
689 **oxidation markers, dityrosine and advanced oxidation protein products**
690 **in Cisplatin-induced nephrotoxicity in rats.** *J Vet Med Sci* 2011; 73: 403–7.
- 691 41. Zuwała-Jagiello J, Pazgan-Simon M, Simon K, et al. **Elevated advanced**
692 **oxidation protein products levels in patients with liver cirrhosis.** *Acta*
693 *Biochim Pol* 2009; 56: 679–685.
- 694 42. Negre-Salvayre A, Coatrieux C, Ingueneau C, et al. **Advanced lipid**
695 **peroxidation end products in oxidative damage to proteins. Potential**
696 **role in diseases and therapeutic prospects for the inhibitors.** *Br J*
697 *Pharmacol* 2008; 153: 6–20.
- 698 43. Korman RM, White JD. **Feline CKD: Current therapies - what is**
699 **achievable?** *J Feline Med Surg* 2013; 15: 29–44.
- 700 44. Tabak O, Gelisgen R, Erman H, et al. **Oxidative lipid, protein, and DNA**
701 **damage as oxidative stress markers in vascular complications of**
702 **diabetes mellitus.** *Clin Invest Med* 2011; 34: E163–E171.

- 703 45. Armstrong PJ, Gross KL, Becvarova I, et al. **Normal cats**. In: Hand M,
704 Thatcher C, Remillard R, et al. (eds) *Small animal clinical nutrition*. Topeka:
705 Mark Morris institute, 2010, pp. 361–372.
- 706 46. Fédération européenne de l'industrie des aliments pour animaux
707 familiers (FEDIAF). **Nutritional Guidelines for Complete and**
708 **Complementary Pet Food for Cats and Dogs**. 2016; 1–100.
- 709 47. Miyata T, Izuhara Y, Sakai H, et al. **Carbonyl stress: Increased carbonyl**
710 **modification of tissue and cellular proteins in uremia**. *Perit Dial Int*
711 1999; 19: 0–3.
- 712 48. Hull GLJ, Woodside J V., Ames JM, et al. **N^{*}-(carboxymethyl)lysine**
713 **content of foods commonly consumed in a Western style diet**. *Food*
714 *Chem* 2012; 131: 170–174.
- 715 49. Ejtahed H-S, Angoorani P, Asghari G, et al. **Dietary Advanced Glycation**
716 **End Products and Risk of Chronic Kidney Disease**. *J Ren Nutr* 2016; 26:
717 308–314.
- 718 50. Rabbani N, Thornalley PJ. **The critical role of methylglyoxal and**
719 **glyoxalase 1 in diabetic nephropathy**. *Diabetes* 2014; 63: 50–52.
- 720 51. Odetti P, Fogarty J, Sell DR, et al. **Chromatographic quantitation of**
721 **plasma and erythrocyte pentosidine in diabetic and uremic subjects**.
722 *Diabetes* 1992; 41: 153–159.
- 723 52. Machowska A, Sun J, Qureshi AQ, et al. **Plasma Pentosidine and Its**
724 **Association with Mortality in Patients with Chronic Kidney Disease**.
725 *PLoS One* 2016; 11: 1–16.

- 726 53. M K, H B, L A, et al. **Pentosidine: Can Be Related To The Etiology Of**
727 **Chronic Kidney Disease?** *Int J Diabetol Vasc Dis Res* 2014; 2: 49–53.
- 728 54. Waanders F, Greven WL, Baynes JW, et al. **Renal accumulation of**
729 **pentosidine in non-diabetic proteinuria-induced renal damage in rats.**
730 *Nephrol Dial Transplant* 2005; 20: 2060–2070.
- 731 55. Chakrabarti S, Syme HM, Brown C a, et al. **Histomorphometry of feline**
732 **chronic kidney disease and correlation with markers of renal**
733 **dysfunction.** *Vet Pathol* 2012; 50: 147–55.
- 734 56. Yoshida N, Okumura K, Aso Y. **High serum pentosidine concentrations**
735 **are associated with increased arterial stiffness and thickness in patients**
736 **with type 2 diabetes.** *Metabolism* 2005; 54: 345–50.
- 737
- 738

Figure 1. NB note misspelling of “pathways” in top left box.




Figure 1. The vicious cycle of Reactive Carbonyl Species (RCS) and Reactive Oxygen Species (ROS) formation pathways. AGEs: advanced glycation end products; ALEs: advanced lipoxidation end products; AOPP: advanced oxidation protein products; aa: amino acids